Veeva Systems
VEEV
$171.36
+8.40%
Veeva Systems Inc. is a global leader in providing cloud-based software solutions exclusively for the life sciences industry, with core products including the Veeva CRM platform for salesforce management and the Veeva Vault platform for content and data management. The company is a dominant, best-of-breed player in its niche, distinguished by deep domain expertise that helps pharmaceutical and biotechnology companies improve efficiency and regulatory compliance. The current investor narrative is shaped by a significant stock price correction, creating a debate between viewing the decline as a long-term buying opportunity for a company with a clear growth runway versus concerns over growth deceleration and broader market rotation away from software stocks.…
VEEV
Veeva Systems
$171.36
Related headlines
VEEV 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veeva Systems's 12-month outlook, with a consensus price target around $222.77 and implied upside of +30.0% versus the current price.
Average Target
$222.77
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$137 - $223
Analyst target range
The stock is covered by at least 9 analysts, as evidenced by the institutional ratings data. The consensus sentiment appears mixed but leans bullish, with recent actions from firms like Citigroup, TD Cowen, Truist Securities, Piper Sandler, Wells Fargo, and RBC Capital maintaining Buy or Overweight/Outperform ratings, while others like Morgan Stanley, UBS, and Canaccord Genuity maintain Hold/Neutral stances. The average target price is not explicitly provided in the data, but the implied upside or downside cannot be calculated without it. The target range is also not specified in the provided dataset. The recent pattern of institutional ratings shows no downgrades in March 2026, with all firms reaffirming their previous ratings. This stability in analyst views amidst a steep price decline suggests the sell-side community may see the correction as overdone relative to the company's fundamentals. A wide target price range would indicate high uncertainty, while a tight range would signal stronger conviction; however, this specific data is unavailable in the provided inputs.
Bulls vs Bears: VEEV Investment Factors
The bull and bear cases are sharply divided on whether the severe price correction represents a compelling buying opportunity for a high-quality business or a justified repricing due to growth deceleration. The bull case is anchored in Veeva's dominant niche position, exceptional profitability, pristine balance sheet, and a valuation that has already compressed significantly from historical peaks. The bear case focuses on the unrelenting technical downtrend, clear signs of growth moderation, and the risk that a premium trailing multiple could compress further. Currently, the bear side has stronger short-term evidence, given the stock's persistent negative momentum and severe underperformance. However, the bull case presents a compelling long-term fundamental argument that is gaining traction as the price nears multi-year lows. The single most important tension in the investment debate is the resolution of growth trajectory: if Veeva can re-accelerate revenue growth or even stabilize at a mid-teens rate, the current valuation (especially the forward P/E of 15.3x) looks attractive. If growth decelerates further, the stock's premium multiple remains at risk.
Bullish
- Dominant Niche with Strong Fundamentals: Veeva is the global leader in cloud software for the life sciences industry, a position supported by a robust 74.5% gross margin and a 29.2% net margin in its latest quarter. This deep domain expertise and high profitability create significant competitive moats.
- Exceptionally Strong Balance Sheet: The company is virtually debt-free with a D/E ratio of 0.013 and holds a strong current ratio of 4.89. It generated $1.39B in trailing twelve-month free cash flow, providing immense financial flexibility to navigate downturns and invest in growth.
- Valuation Compression Creates Opportunity: The stock's trailing P/E of 36.7x has compressed significantly from historical highs above 73x, and its forward P/E of 15.3x implies the market expects strong earnings growth. Trading just 3.4% above its 52-week low of $148.05, much of the negative sentiment appears priced in.
- Analyst Sentiment Remains Stable: Despite a 45.5% one-year price decline, analyst ratings from major firms (Citigroup, TD Cowen, Wells Fargo, RBC) have remained steady with Buy/Outperform ratings, suggesting the sell-side views the correction as overdone relative to the company's durable fundamentals.
Bearish
- Severe Technical Downtrend and Underperformance: The stock is down 45.5% over the past year and 30.9% over six months, underperforming the SPY by over 70 percentage points. It is trading deep in a downtrend, near its 52-week low, with negative momentum across all measured periods, indicating persistent selling pressure.
- Growth Deceleration is Evident: While revenue grew 16% YoY in the latest quarter, the sequential quarterly growth rate from Q1 ($759M) to Q4 ($836M) shows a pattern of moderation. This deceleration challenges the premium valuation historically afforded to high-growth software stocks.
- Elevated Trailing Valuation vs. Sector: Despite the sharp decline, the trailing P/E of 36.7x remains elevated compared to typical sector averages. This premium multiple leaves the stock vulnerable to further compression if growth continues to slow or if market sentiment remains negative towards software.
- High Sensitivity to Market Sentiment: With a beta of 0.95, VEEV moves nearly in line with the market. In a risk-off environment favoring defensive sectors over growth stocks (as noted in recent news), it faces headwinds from broader sector rotation, which has contributed to its significant underperformance.
VEEV Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -45.53% and a 6-month decline of -30.90%. As of the latest close of $153.30, the price is trading near the bottom of its 52-week range, approximately 3.4% above the 52-week low of $148.05 and 50.6% below the 52-week high of $310.50. This positioning deep in the lower quartile of its range suggests the stock is in a state of severe technical weakness, potentially presenting a deep-value opportunity but also signaling significant negative momentum that has yet to show signs of reversal. Recent momentum remains negative and is decelerating, with a 3-month loss of -16.72% and a 1-month loss of -6.13%. This short-term weakness confirms the longer-term downtrend, with no meaningful divergence to suggest a bottom is forming. The stock has demonstrated severe underperformance relative to the broader market, evidenced by a 1-year relative strength of -70.52% versus the SPY. Key technical levels are clearly defined, with immediate support at the 52-week low of $148.05 and major resistance far above at the 52-week high of $310.50. A decisive breakdown below $148 could trigger another leg down, while any recovery would face a long climb through multiple resistance zones. With a beta of 0.949, the stock's volatility is roughly in line with the market, but its specific, steep decline highlights significant company or sector-specific headwinds rather than broad market beta.
Beta
0.95
0.95x market volatility
Max Drawdown
-50.5%
Largest decline past year
52-Week Range
$148-$311
Price range past year
Annual Return
-39.1%
Cumulative gain past year
| Period | VEEV Return | S&P 500 |
|---|---|---|
| 1m | +8.1% | -2.9% |
| 3m | -0.7% | +15.0% |
| 6m | -23.7% | +5.6% |
| 1y | -39.1% | +19.1% |
| ytd | -21.9% | +6.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VEEV Fundamental Analysis
Revenue growth remains positive but has shown signs of sequential deceleration. The most recent quarterly revenue (Q4 FY2026 ending Jan 31, 2026) was $835.95 million, representing a solid year-over-year growth rate of 15.96%. However, examining the sequential quarterly revenue trend from the provided income statements shows a pattern of $759.04M (Q1), $789.08M (Q2), $811.24M (Q3), to $835.95M (Q4), indicating growth is continuing but at a potentially moderating pace quarter-over-quarter. The company is highly profitable with strong margins. Net income for the latest quarter was $244.20 million, translating to a robust net margin of 29.21%. The gross margin was an exceptional 74.46%, consistent with a high-margin software business. Profitability has been stable, with net margins hovering around 29-30% over the last several reported quarters, demonstrating the company's ability to convert revenue efficiently to earnings despite the top-line growth moderation. The balance sheet is exceptionally strong with minimal debt and significant cash generation. The debt-to-equity ratio is a negligible 0.013, indicating a virtually debt-free capital structure. The company generated $138.97 million in free cash flow for the quarter and has a trailing twelve-month free cash flow of $1.39 billion. The current ratio of 4.89 and return on equity of 12.60% further underscore a financially healthy company with ample liquidity to fund operations and growth internally without reliance on external financing.
Quarterly Revenue
$835951000.0B
2026-01
Revenue YoY Growth
+0.15%
YoY Comparison
Gross Margin
+0.74%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VEEV Overvalued?
Given the company's consistent profitability with net income of $244.20 million, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 36.72x, while the forward PE is significantly lower at 15.28x. This substantial gap implies the market expects a meaningful acceleration in earnings growth in the coming year, likely factoring in the company's guidance or analyst estimates for improved profitability. Compared to sector averages, Veeva's trailing PE of 36.72x is elevated, typically signaling a premium valuation. This premium has historically been justified by its leadership position, high margins, and predictable growth within the life sciences vertical. However, the current premium must be weighed against the recent growth deceleration trend observed in the fundamental analysis. Historically, the stock's own valuation has compressed significantly. The current trailing PE of 36.72x is well below the historical highs seen in recent years, such as the 57.86x recorded in Q2 of FY2026 (July 2025) and the 73.36x from July 2023. This compression places the valuation closer to the lower end of its multi-year range, suggesting much of the multiple derating has already occurred and the stock may be pricing in a more conservative growth outlook.
PE
36.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 34x~117x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Veeva's primary financial risk is not solvency or liquidity—its balance sheet is fortress-like—but rather growth sustainability to justify its valuation. The company's trailing P/E of 36.7x, while compressed, remains elevated and is predicated on continued high-quality earnings growth. The sequential moderation in quarterly revenue growth from Q1 to Q4 FY2026 ($759M to $836M) introduces execution risk. Furthermore, its entire revenue is concentrated in the life sciences vertical, making it susceptible to industry-specific downturns in biopharma R&D or regulatory spending, though its high 74.5% gross margin provides a buffer.
Market & Competitive Risks: The stock faces significant valuation compression risk, having already derated from a P/E above 73x to 36.7x. If growth decelerates further, the multiple could contract toward the sector median, implying additional downside. Competitive risks, while muted due to Veeva's domain expertise, could emerge from larger enterprise software players or new entrants. The stock's beta of 0.95 indicates it is not a defensive safe haven and remains correlated to broader market swings, particularly negative for growth stocks in a rising rate environment, as highlighted by recent news on geopolitical uncertainty favoring defensive sectors.
Worst-Case Scenario: The worst-case scenario involves a combination of a deeper-than-expected slowdown in life sciences IT spending, a failure to re-accelerate growth, and a sustained market rotation away from premium-valued software stocks. This could trigger a further de-rating of the forward P/E from 15.3x toward low-double digits and push the stock price toward or below its 52-week low of $148.05. A realistic downside scenario from the current price of $153.30 could see a decline of 20-30%, revisiting the $110-$125 range if earnings estimates are cut and sentiment sours further, representing a potential loss of approximately -28% to the $110 level.
